Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Spotify (SPOT) PT raised to $520 at Cantor Fitzgerald After Investor Day
-
Custom Truck One Source (CTOS) PT Raised to $13 at Cantor Fitzgerald
-
Marvell (MRVL) PT Raised to $190 at Cantor Fitzgerald Ahead of April Q Results
-
Elastic NV. (ESTC) PT Lowered to $59 at Cantor Fitzgerald
-
MongoDB (MDB) PT Raised to $416 at Cantor Fitzgerald
-
Snowflake Inc. (SNOW) PT Lowered to $225 at Cantor Fitzgerald
-
Artiva Biotherapeutics (ARTV) Reiterated at Overweight by Cantor Fitzgerald
-
Lemonade (LMND) Reiterated at Overweight by Cantor Fitzgerald After CFO Meeting
-
Softbank Group (9984:JP) (SFTBY) PT Raised to JPY6,900 at Cantor Fitzgerald
-
Intuitive Machines Inc. (LUNR) PT Raised to $43 at Cantor Fitzgerald on Reaffirmed Guidance
-
Editas Medicine announces public offering of stock and warrants
-
Editas Medicine Announces Proposed Public Offering
-
Newmark names Kyle Lutnick as chief strategy officer
-
Newmark Appoints Kyle Lutnick as Chief Strategy Officer
-
Ideaya Biosciences (IDYA) Reiterated at Overweight by Cantor Fitzgerald
-
Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
-
ORIC Pharmaceuticals (ORIC) Reiterated at Overweight by Cantor Fitzgerald
-
Workday (WDAY) Reiterated at Overweight by Cantor Fitzgerald After Q1 Results
-
Zoom Video (ZM) PT Raised to $104 at Cantor Fitzgerald on Raised Estimates
-
Palantir (PLTR) Reiterated at Neutral by Cantor Fitzgerald After CFO Meet
-
Centuri to Participate in Upcoming Second Quarter 2026 Investor Conferences
-
Rocket Lab stock falls after $3 billion share sale agreement
-
Ultragenyx Pharma (RARE) PT Raised to $96 at Cantor Fitzgerald
-
Cantor Fitzgerald on Top Pick VIDIA (NVDA): 'we remain all-in on NVDA'
-
Cantor Fitzgerald Starts Connect Biopharma Holdings Ltd (CNTB) at Overweight
-
Cantor Receives ADGM Approval, Expanding Middle East Investment Banking Platform
-
Cantor Fitzgerald Starts Aligos Therapeutics Inc. (ALGS) at Overweight
-
Securitize Reports First Quarter 2026 Results
-
Workday (WDAY) PT Lowered to $160 at Cantor Fitzgerald on Subdued Expectations
-
Protara Therapeutics (TARA) Reiterated at Overweight by Cantor Fitzgerald
-
Palo Alto Networks (PANW) PT Raised to $285 at Cantor Fitzgerald Ahead of June Earnings
-
Zscaler (ZS) Reiterated at Overweight by Cantor Fitzgerald Ahead of Q3 Earnings
-
CrowdStrike Holdings (CRWD) PT Raised to $700 at Cantor Fitzgerald Ahead of Q1 Results
-
Cantor Fitzgerald Starts X-Energy Inc (XE) at Overweight
-
Form 4 Cantor Equity Partners For: May 15 Filed by: CANTOR FITZGERALD, L. P.
-
Form N-23C3A CANTOR FITZGERALD INFRAS For: May 19
-
enCore Energy (EU) PT Lowered to $4.50 at Cantor Fitzgerald
-
Primoris Services Corporation (PRIM) PT Raised to $124 at Cantor Fitzgerald
-
Inhibikase Therapeutics (IKT) Reiterated at Overweight by Cantor Fitzgerald
-
Ameresco (AMRC) PT Raised to $45 at Cantor Fitzgerald on Neogenyx JV CLose
-
Hive Digital Technologies (HIVE) PT Raised to $4.60 at Cantor Fitzgerald
-
Agilysys (AGYS) Reiterated at Overweight by Cantor Fitzgerald on Q4 Results
-
WAVE Life Sciences (WVE) Reiterated at Overweight by Cantor Fitzgerald on WVE-006 Data
-
Intuitive Machines Inc. (LUNR) PT Raised to $43 at Cantor Fitzgerald on Q1 Results
-
Cantor Fitzgerald Reiterates Overweight Rating on CrowdStrike Holdings (CRWD)
-
Cantor Fitzgerald Bullish on Rocket Lab USA (RKLB) Following Q1 Print on Multiple Moats
-
Cantor Fitzgerald Reiterates Overweight Rating on Analog Devices (ADI)
-
Realty Income (O) PT Lowered to $65 at Cantor Fitzgerald
-
Regeneron Pharma (REGN) PT Lowered to $785 at Cantor Fitzgerald on Disappointing Trial Results
-
NVIDIA (NVDA) PT Raised to $350 at Cantor Fitzgerald on 'Clear Vision' for YoY Growth Through 2029

